Revisión 2015 (revisión en vídeo por el autor)

Los resultados de estudios aleatorizados fase III RT vs RT+HT arrojan los siguientes resultados [1]:

 

• Mama localmente avanzado/recidivado: Complete local response in breast: RT (88/181, 48.6%) vs. RT + HT (122/198, 61.6%), Odds ratio = 2.10 (95% CI, 1.34–3.30), p = 0.001

 

• Cérvix en tratamiento:Complete local response in cervix: RT+/-QR: RT (173/263, 65.7%) vs. RT + HT (200/251, 79.6%), Odds ratio = 2.19 (95% CI, 1.45–3.32), p < 0.001

 

• Cabeza y cuello avanzado: Complete local response in head & neck: RT (183/364, 50.3%) vs. RT + HT (266/353, 75.3%), Odds ratio = 3.71 (95% CI, 2.55–5.38), p < 0.001

 

• Colorrectal avanzado/recidivado: Complete local response in rectum: RT (16/205, 7.8%) vs. RT + HT (36/208, 17.3%), Odds ratio = 2.15 (95% CI, 1.10–4.20), p = 0.025

 

• Vejiga localmente avanzado/recidivado: Complete local response in urinary bladder: RT (35/86, 40.6%) vs. RT + HT (69/118, 58.4%), (Odds ratio = 2.40 (95% CI, 1.25–4.62), p = 0.009

 

• Esófago preoperatorio: Complete local response in esophagus: RT (24/132, 18.2%) vs. RT + HT (47/162, 29%), Odds ratio = 2.64 (95% CI, 1.34–5.20), p = 0.005

 

• Pulmón avanzado de células no pequeñas: Complete local response in lung: RT (2/70, 2.8%) vs. RT + HT (7/59, 11.8%), Odds ratio = 2.69 (95% CI, 0.51–14.22), p = 0.243

 

• Superficiales: Complete local response in superficial tumors: RT (57/169, 33.7%) vs. RT + HT (75/175, 42.8%), Odds ratio = 1.48 (95% CI, 0.94–2.32), p = 0.091

 

​

En total: Overall complete local response in all sites: RT (685/1717, 39.8%) vs. RT + HT (967/1761, 54.9%), I2 = 28.49, Odds ratio = 2.30 (95% CI, 1.95–2.72), p < 0.001